Article successfully added.

CyFlow™ CD69 APC

CyFlow™ CD69 APC
Alternative Name: AIM , VEA
Antibody: Yes
Antigen: CD69
Application: Flow cytometry
Clonality: monoclonal
Clone: FN50
Emission Maximum: 660 nm
Excitation Maximum: 650 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: APC
Isotype: IgG1
Laser: Red
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BP059739

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Quantity 100 tests Volume 1.0 mL Immunogen Anti-μ-stimulated human B lymphocytes... more
CyFlow™ CD69 APC
Quantity100 tests
Volume1.0 mL
ImmunogenAnti-μ-stimulated human B lymphocytes
Background InformationCD69 (CLEC2C; C-type lectin domain family 2 C or AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford University Press, Oxford. 1989; 1‑1820. < NLM ID: 8914679 > | López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C‑type animal lectin superfamily of signal‑transmitting receptors. J Exp Med. 1993 Aug 1; 178(2):537‑47. < PMID: 8340758 > | Nielsen SD, Afzelius P, Ersbøll AK, Nielsen JO, Hansen JE: Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV‑infected patients. Clin Exp Immunol. 1998 Oct; 114(1):66‑72. < PMID: 9764605 > | Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May; 19(5):675‑84. < PMID: 17446208 > | Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV‑1‑infected autologous CD4 primary T cells: requirement for IFN‑mediated NK activation by plasmacytoid dendritic cells. J Immunol. 2007 Aug 15; 179(4):2097‑104. < PMID: 17675468 > | Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I: CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest. 2007 Nov; 37(11):887‑96. < PMID: 17973783 > | Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T‑cell subsets in HIV‑1 disease. Scand J Clin Lab Invest. 2008; 68(3):233‑41. < PMID: 17917998 > | Hrdinka M, Dráber P, Stepánek O, Ormsby T, Otáhal P, Angelisová P, Brdicka T, Paces J, Horejsí V, Drbal K: PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J Biol Chem. 2011 Jun 3; 286(22):19617‑29. < PMID: 21460222 > | Ohradanova‐Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco‐Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. FrontImmunol. 2018 Apr 27; 9:852. < PMID: 29780382 >